ICGs, particularly the key members such as CTLA-4 and PD-1, are profoundly involved in immune tolerance and proliferation of glioma cells, and their blockage might inhibit the progression of gliomas (Ghouzlani et al., 2021). This evidence concerns the gene PDCD1 and central nervous system cancer.